BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Lurasidone readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Lurasidone\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05480150-9208@assetmemo.bio
DTSTAMP:20261121T004056Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Lurasidone: Phase na readout est. (NCT05480150)
DESCRIPTION:Lurasidone\, phase na.\nStudy: Chinese Longitudinal and Systema
 tic Study of Bioplar Disorder\nEstimated primary completion: 31 December 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/lurasidone#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05480150
URL:https://assetmemo.bio/drug/lurasidone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07781293-9208@assetmemo.bio
DTSTAMP:20261121T004056Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Lurasidone: Phase 3 readout est. (NCT07781293)
DESCRIPTION:Lurasidone\, phase 3.\nStudy: Study of Lurasidone as Adjunctive
  Treatment in Patients With Major Depressive Disorder With Inadequate Resp
 onse to Antidepressant Monotherapy\nEstimated primary completion: October 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/lurasidone#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07781293
URL:https://assetmemo.bio/drug/lurasidone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07806227-9208@assetmemo.bio
DTSTAMP:20261121T004056Z
DTSTART;VALUE=DATE:20280730
DTEND;VALUE=DATE:20280731
SUMMARY:Lurasidone: Phase 4 readout est. (NCT07806227)
DESCRIPTION:Lurasidone\, phase 4.\nStudy: Broadband Near Infrared Spectrosc
 opy to Understand the Role of Brain Cytochrome C Oxidase in Bipolar Disord
 er\nEstimated primary completion: 30 July 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/lurasidone#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07806227
URL:https://assetmemo.bio/drug/lurasidone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06433635-9208@assetmemo.bio
DTSTAMP:20261121T004056Z
DTSTART;VALUE=DATE:20300228
DTEND;VALUE=DATE:20300301
SUMMARY:Lurasidone: Phase 4 readout est. (NCT06433635)
DESCRIPTION:Lurasidone\, phase 4\, Bipolar Depression.\nStudy: Sequential M
 ultiple Assignment Randomized Trial for Bipolar Depression\nEstimated prim
 ary completion: 28 February 2030. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/lurasidone#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06433635
URL:https://assetmemo.bio/drug/lurasidone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
